Posted by Michael Wonder on 23 Sep 2020
ICER issues final report and policy recommendations on treatments for cystic fibrosis
23 September 2020 - Independent appraisal committee unanimously concludes that Trikafta delivers substantial benefits for patients, family members, and society.
Nonetheless, analyses suggest that the price set by the manufacturer would need to be deeply discounted to align fairly with these benefits and ensure that they are not outweighed by the negative health effects for others resulting from increasing health care costs.
